

# Regional Framework for Action on Implementation of the **End TB Strategy** in the Western Pacific, 2016–2020





# Regional Framework for Action on Implementation of the **End TB Strategy** in the Western Pacific, 2016–2020

WHO Library Cataloguing-in-Publication Data

Regional framework for action on implementation of the end TB strategy in the Western Pacific, 2016–2020

1. Guideline. 2. Regional health planning. 3. Tuberculosis.

I. World Health Organization Regional Office for the Western Pacific.

ISBN 978 92 9061 755 6 (NLM Classification: WF200)

© World Health Organization 2016

All rights reserved.

Publications of the World Health Organization are available on the WHO website ([www.who.int](http://www.who.int)) or can be purchased from WHO Press: World Health Organization – 20, avenue Appia – 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)). For WHO Western Pacific Region publications, requests for permission to reproduce should be addressed to Publications Office, World Health Organization, Regional Office for the Western Pacific, P.O. Box 2932, 1000, Manila, Philippines, fax: +632 521 1036, e-mail: [publications@wpro.who.int](mailto:publications@wpro.who.int)

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate borderlines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Cover, photo credit: ©WHO/Y. Shimizu

# CONTENTS

Abbreviations.....	iv
Foreword .....	v
Executive summary.....	vii

## **PART A. Background**

1. Regional progress.....	1
2. Challenges.....	3
3. The End TB Strategy, global targets and operational indicators.....	5
4. The rationale, purpose and target audience.....	7
5. Regional relevance and focus.....	8

## **PART B. Implementation of the Regional Framework**

1. <b>Pillar 1: Integrated, people-centred care and prevention</b> .....	13
1.1 Treatment and care for all TB patients.....	14
1.2 Strong laboratory networks to find all TB cases.....	31
1.3 Latent TB infection and BCG vaccination.....	34
2. <b>Pillar 2: Bold policies and supportive systems</b> .....	37
2.1 Governance and stewardship.....	38
2.2 Engagement and partnerships.....	50
2.3 Addressing social determinants and social protection.....	54
3. <b>Pillar 3: Intensified research and innovation</b> .....	62
3.1 Enhancing TB research capacity for development, rapid uptake and optimum use of new interventions.....	62

## ABBREVIATIONS

<b>AIDS</b>	acquired immunodeficiency syndrome
<b>ART</b>	antiretroviral treatment
<b>BCG</b>	bacille Calmette–Guérin (vaccine)
<b>CPT</b>	co-trimoxazole preventive therapy
<b>DST</b>	drug susceptibility testing
<b>DOT</b>	directly observed therapy
<b>DOTS</b>	directly observed treatment, short-course
<b>GDF</b>	Global Drug Facility
<b>HIV</b>	human immunodeficiency virus
<b>HiAP</b>	health in all policies
<b>IPT</b>	isoniazid preventive therapy
<b>ISO</b>	International Organization for Standardization
<b>ISTC</b>	International Standards for Tuberculosis Care
<b>LED</b>	light-emitting diode
<b>LPA</b>	line probe assay
<b>LTBI</b>	latent TB infection
<b>MDGs</b>	Millennium Development Goals
<b>MDR-TB</b>	multidrug-resistant tuberculosis
<b>NCDs</b>	noncommunicable diseases
<b>NMRA</b>	national medicine regulatory authority
<b>NSP</b>	national (TB) strategic plan
<b>NTP</b>	National Tuberculosis Programme
<b>PAF</b>	population attributable fraction
<b>PATLAB</b>	Pacific TB Laboratory Initiative
<b>PMDT</b>	programmatic management of drug-resistant tuberculosis
<b>RFLP</b>	restriction fragment length polymorphism
<b>rGLC</b>	regional Green Light Committee
<b>SRL</b>	supranational reference laboratory
<b>TB</b>	tuberculosis
<b>UHC</b>	universal health coverage
<b>VNTR</b>	variable number tandem repeats WHO World Health Organization
<b>WRDs</b>	WHO-recommended diagnostics
<b>XDR-TB</b>	extensively drug-resistant tuberculosis

# FOREWORD

Progress in reducing the burden of tuberculosis (TB) in the Western Pacific Region has been remarkable. Since 1990, concerted efforts have reduced TB prevalence by over 55% and TB deaths by over 78%. An estimated 9.5 million lives have been saved since 2000. Today, 1.4 million patients are treated annually. With incidence continuously declining, the Western Pacific Region has achieved the TB-related targets associated with the Millennium Development Goals.

However, much work remains to be done to further reduce the burden of TB. Despite big reductions, TB continues to claim more than 100 000 lives every year in the Region. In 2014, 1.6 million people fell ill with TB, shattering lives and livelihoods. In May 2014, the World Health Assembly adopted a new global strategy for TB, the *End TB Strategy*. The strategy sets ambitious targets: a 90% reduction in incidence and a 95% reduction in mortality by 2035, with no families facing catastrophic costs due to TB by 2020.

Drug-resistant TB is a growing threat to global and regional health security. Health systems with weak drug regulations and substandard care continue to generate drug-resistance. Despite substantial investment, the majority of drug-resistant TB cases are undiagnosed or treated with a low rate of success.

TB concentrates in vulnerable populations, among those least able to cope with the financial burden of illness. Basic TB services are free in nearly all countries in the Region; nevertheless, patients often still suffer heavy financial burden. The *End TB Strategy's* target of “no affected families facing catastrophic costs due to TB” must be achieved through ensuring financial risk protection for TB patients in line with national efforts towards universal health coverage.

Weak regulatory mechanisms diminish TB control by allowing inadequate TB treatment. Ministries of health are best positioned to coordinate and guide national responses. Under government stewardship, strong regulatory mechanisms should be in place to support TB control, including mandatory disease notification, harmonized drug regulatory policies and standards of care that include infection control.

To achieve the End TB Strategy, intensified research and development are also required. Globally and regionally, a critical need exists for continued advocacy, information-sharing platforms and enhanced TB research investment. Building national research capacity is essential, especially in low- and middle-income countries with substantial TB burden.

The Regional Framework for Action on Implementation of the *End TB Strategy* in the Western Pacific 2016–2020 aims to adapt the End TB Strategy to the particular circumstances of countries and areas in the Region. The endorsement of this framework by the sixty-sixth Regional Committee for the Western Pacific represents the strong commitment of Member States to build and maintain bold national efforts for TB control until the vision of zero deaths, disease and suffering due to tuberculosis is achieved.



Shin Young-soo, MD, Ph.D.  
Regional Director

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_27032](https://www.yunbaogao.cn/report/index/report?reportId=5_27032)

